Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
Sanaz N GhafouriJohn TimmermanSarah LarsonMonica D MeadPublished in: Bone marrow transplantation (2020)